trial_id	recruitmentstate	approvaldate	actualstartdate	drug_classes	combo_list	combo_classes	studytitle	healthcondition	postcode	ext_weblink
ACTRN12614001248651	NSW	28/11/2014	29/09/2014	glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic; glucocorticoid	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid; glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Malignant Pleural Mesothelioma; Advanced Non Small Cell Lung Cancer	2050 - Camperdown; 2139 - Concord Repatriation Hospital; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001248651
ACTRN12618001121257	QLD	6/07/2018	22/05/2019	anti-PD-1_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	Denosumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	4029 - Herston; 4032 - Chermside; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001121257
ACTRN12618001337268		8/08/2018					The safety and efficacy of immunotherapy with the activited T cells from from umbilical cord blood mononuclear cells ex vivo for small cell lung cancer,Kidney cancer and Primary liver cancer treatment	Histopathologically confirmed Liver cancer; Histopathologically confirmed Kidney cancer; Histopathologically confirmed small cell lung cancer (SCLC)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001337268
ACTRN12618001742268	SA, QLD, WA, VIC, NSW, TAS	23/10/2018	4/04/2019	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody	Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite	A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE).	EGFR mutant advanced non small cell lung cancer.	4102 - Woolloongabba; 3000 - Melbourne; 4032 - Chermside; 3168 - Clayton; 7000 - Hobart; 2200 - Bankstown; 6009 - Nedlands; 2217 - Kogarah; 3065 - Fitzroy; 2250 - Gosford; 2170 - Liverpool; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001742268
ACTRN12619000769189	WA	23/05/2019					A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.	Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000769189
ACTRN12619000844145	VIC, NSW	13/06/2019	14/06/2019	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor	Crizotinib + Lorlatinib; Lorlatinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ROS1_inhibitor	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	2065 - St Leonards; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000844145
ACTRN12620000861954	NSW	28/08/2020		BRAF_V600_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Cobimetinib + Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor	Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	Cancer; non-small cell lung cancer	2217 - Kogarah; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000861954
ACTRN12620001198910	NSW	10/11/2020	15/04/2021	platinum-based_antineoplastic_agent + taxane; taxane; platinum-based_antineoplastic_agent; radiotherapy; anti-PD-L1_monoclonal_antibody	Carboplatin + Paclitaxel; Durvalumab; radiotherapy	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2148 - Blacktown; 2298 - Waratah; 2170 - Liverpool; 2560 - Campbelltown; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000312842	WA, TAS, VIC, NSW, QLD, SA, ACT	22/03/2021	3/09/2021	ALK_inhibitor,second_generation	Alectinib	ALK_inhibitor,second_generation	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	Cancer; ALK gene alterations; Non-small cell lung cancer	7000 - Hobart; 2065 - St Leonards; 4102 - Woolloongabba; 3000 - Melbourne; 5000 - Adelaide; 2217 - Kogarah; 6009 - Nedlands; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000811808	NT, QLD, TAS, VIC, NSW, WA, ACT, SA	28/06/2021	9/11/2021	MET_inhibitor,type_1	Tepotinib	MET_inhibitor,type_1	A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling	Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations	3084 - Heidelberg; 3065 - Fitzroy; 2605 - Garran; 2217 - Kogarah; 6009 - Nedlands; 2145 - Westmead; 0810 - Tiwi; 2065 - St Leonards; 7000 - Hobart; 5000 - Adelaide; 3000 - Melbourne; 4032 - Chermside; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000811808
NCT02408861	NSW	6/04/2015	27/08/2015	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Refractory Classic Hodgkin Lymphoma; Advanced Malignant Solid Neoplasm; Kaposi Sarcoma; HIV Infection; Anal Carcinoma; Unresectable Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma	2010 - Darlinghurst - Saint Vincent's Hospital - (Suspended); 2052 - Sydney - University of New South Wales	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02477826	ACT, SA, QLD, NSW, VIC, WA	23/06/2015	5/08/2015	anti-CTLA-4_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; taxane	Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na√Øve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital - (Active, not recruiting); 2250 - Gosford - Local Institution - (Active, not recruiting); 2340 - Tamworth - Tamworth Hospital - (Active, not recruiting); 2605 - Garran - Local Institution - (Active, not recruiting); 3065 - Fitzroy - St Vincent's Hospital - (Active, not recruiting); 3168 - Clayton - Local Institution - (Active, not recruiting); 4102 - Brisbane - Princess Alexandra Hospital - (Active, not recruiting); 6150 - Murdoch - Local Institution - (Active, not recruiting); 6150 - Perth - Local Institution - (Active, not recruiting); Elizabeth Vale - Local Institution - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT02477826
NCT02568267	NSW, VIC, SA	5/10/2015	19/11/2015	ALK_inhibitor,third_generation; MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; TRK_inhibitor,first_generation	Crizotinib; Entrectinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor; TRK_inhibitor,first_generation	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Sarcomas; Head and Neck Neoplasms; Salivary Gland Cancers; Neuroendocrine Tumors; Breast Cancer; Primary Brain Tumors; Colorectal Cancer; Ovarian Cancer; Papillary Thyroid Cancer; Adult Solid Tumor; Cholangiocarcinoma; Renal Cell Carcinoma; Pancreatic Cancer; Non-Small Cell Lung Cancer; Melanoma; Lymphoma, Large-Cell, Anaplastic	2170 - Liverpool - Liverpool Hospital; 2305 - New Lambton Heights - Newcastle Private Hospital - (Active, not recruiting); 2640 - Albury - Border Medical Oncology Research Unit - (Withdrawn); 3084 - Heidelberg - Austin Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02609776	QLD, WA, NSW, VIC	20/11/2015	24/05/2016	antimetabolite; bispecific_c-Met_EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	Amivantamab + Lazertinib	EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Non-Small-Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2217 - Kogarah - St George Hospital; 3084 - Heidelberg - Austin Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 6150 - Murdoch - St John of God Hospital Murdoch - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT02609776
NCT02628067	NSW	11/12/2015	18/12/2015	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Anal Cancer; Thyroid Cancer; Biliary Cancer; Colorectal Carcinoma; Mesothelioma; Salivary Gland Cancer; Parotid Gland Cancer; Salivary Gland Carcinoma; Vulvar Cancer; Carcinoid Tumor; Anal Carcinoma; Cervical Carcinoma; Neuroendocrine Tumor; Small Cell Lung Carcinoma; Cholangiocarcinoma; Thyroid Carcinoma; Small Cell Lung Cancer (SCLC); Advanced Solid Tumors; Cervical Cancer; Endometrial Cancer; Salivary Cancer; Vulvar Carcinoma; Endometrial Carcinoma; Bile Duct Cancer; Advanced Cancer	North Ryde - Merck Sharp &amp; Dohme	https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02775435	NSW	15/05/2016	9/06/2016	placebo; glucocorticoid; platinum-based_antineoplastic_agent + taxane; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT02857270	NSW, WA	5/08/2016	29/09/2016	benzodiazepam; BRAF_V600_inhibitor; CDK4/6_inhibitor + ERK_inhibitor; antimetabolite; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor; CDK4/6_inhibitor; anti-EGFR_monoclonal_antibody; taxane; ERK_inhibitor + benzodiazepam; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody	Abemaciclib + LY3214996; Cetuximab + Encorafenib + LY3214996; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam	BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor + benzodiazepam	A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer	Colorectal Cancer; Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Advanced Cancer	2010 - Sydney - St Vincent's Hospital; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT02857270
NCT02974725	VIC, NSW	28/11/2016	24/02/2017	RAF_dimer_inhibitor; ERK_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + LXH254; LXH254 + Ribociclib; LXH254 + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	Melanoma; Non-Small Cell Lung Cancer	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site - (Completed); 3181 - Prahran - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT02974725
NCT03138889	VIC	3/05/2017	9/06/2017	antimetabolite; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane; IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Non-Small Cell Lung Cancer	3121 - Richmond - Epworth HealthCare	https://clinicaltrials.gov/ct2/show/NCT03138889
NCT03157128	NSW, VIC	17/05/2017	2/05/2017	RET_inhibitor	Selpercatinib	RET_inhibitor	A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Colon Cancer; Medullary Thyroid Cancer; Non-Small Cell Lung Cancer; Any Solid Tumor	2065 - St. Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03170960	VIC, NSW	31/05/2017	5/09/2017	AXL_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; MET_inhibitor,type_2; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; platinum-based_antineoplastic_agent; RET_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; taxane; ROS1_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor	Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Atezolizumab + Cabozantinib; Cisplatin; Docetaxel; Irinotecan + Oxaliplatin	AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; taxane	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Castration-resistant Prostate Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Cancer; Triple Negative Breast Cancer; Colorectal Cancer; Ovarian Cancer; Head and Neck Cancer; Endometrial Cancer; Renal Cell Carcinoma; Lower Esophageal Cancer; Urothelial Carcinoma; Differentiated Thyroid Cancer; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer	2031 - Randwick - Exelixis Clinical Site #123; 2050 - Camperdown - Exelixis Clinical Site #101; 2109 - North Ryde - Exelixis Clinical Site #112; 2250 - Gosford - Exelixis Clinical Site #115; 2640 - Albury - Exelixis Clinical Site #98; 3021 - St Albans - Exelixis Clinical Site #99	https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03175224	SA, WA, VIC, NSW	5/06/2017	27/09/2017	MET_inhibitor,type_1	Bozitinib	MET_inhibitor,type_1	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Brain Tumor; Solid Tumor; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Glioblastoma Multiforme; Renal Cancer; NSCLC; Advanced Cancer; Lung Cancer	Albury - Border Medical Oncology; Bedford Park - Flinders Medical Centre; Melbourne - St Vincents Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary Central Districts Hospita	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03178552	QLD, VIC, NSW, WA, NZ, SA	7/06/2017	22/09/2017	anti-PD-L1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; platinum-based_antineoplastic_agent; ALK_inhibitor,third_generation; MEK_inhibitor; TRK_inhibitor,first_generation; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; BRAF_V600_inhibitor; anti-VEGF_monoclonal_antibody; ALK_inhibitor,second_generation	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Entrectinib	ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital; 2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 3084 - Heidelberg - Austin Hospital; Medical Oncology; 4032 - Chermside - The Prince Charles Hospital; Oncology Dept.; 5037 - Kurralta Park - Ashford Cancer Center Research - (Completed); 6009 - Nedlands - Sir Charles Gairdner Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT03207867	NSW	5/07/2017	28/08/2017	adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	NIR178; NIR178 + Spartalizumab	adenosine_A2A_receptor_antagonist; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	Head and Neck Cancer; TNBC, Triple Negative Breast Cancer; RCC, Renal Cell Cancer; MSS, Microsatellite Stable Colon Cancer; NSCLC, Non Small Cell Lung Cancer; Urothelial Cancer; DLBCL, Diffused Large B Cell Lymphoma; Melanoma; mCRPC, Metastatic Castration Resistant Prostate Cancer 0 0; Pancreatic Cancer	2148 - Blacktown - Novartis Investigative Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03207867
NCT03212404	QLD, NZ, VIC, NSW	11/07/2017	20/09/2017	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Lung Neoplasms; Carcinoma, Small Cell; Melanoma; Urothelial Carcinoma; Non Hodgkin Lymphoma; Classical Hodgkin Lymphoma; Renal Cell Carcinoma; Endometrial Cancer; Merkel Cell Carcinoma; Head and Neck Cancer; Cutaneous Squamous Cell Carcinoma; Malignant Mesothelioma, Advanced; Carcinoma, Non-Small-Cell Lung	2500 - Wollongong - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site; 4101 - South Brisbane - Research Site; 4102 - Woolloongabba - Research Site; 4120 - Greenslopes - Research Site; 4217 - Benowa - Research Site; 4556 - Buderim - Research Site; 8140 - Christchurch - Research Site	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03319628	NSW, VIC	24/10/2017	12/12/2017	anti-NaPi2b_antibody-drug_conjugate	XMT-1536	anti-NaPi2b_antibody-drug_conjugate	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Non Small Cell Lung Cancer Metastatic; Platinum Resistant Ovarian Cancer	2148 - Blacktown - Blacktown Hospital; Camperdown - Chris O'Brien Lifehouse; Heidelberg - Austin Health - Olivia Newton John Cancer Center; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03319940	NSW	24/10/2017	26/12/2017	anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_DLL3; bispecific_T_cell_engager_targeting_DLL3; anti-PD-1_monoclonal_antibody	AMG 757; AMG 757 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_DLL3; bispecific_T_cell_engager_targeting_DLL3	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	Small Cell Lung Carcinoma	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03337698	VIC, NSW	9/11/2017	2/01/2018	anti-Trop2_antibody-drug_conjugate; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-IL-6_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CEA/CD3_bispecific_antibody; anti-VEGF_monoclonal_antibody; antimetabolite; anti-CEA/CD3_bispecific_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; radiotherapy; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Docetaxel	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-CEA/CD3_bispecific_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; taxane	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown - Blacktown Hospital; 3002 - East Melbourne - Peter Mac Callum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT03337698
NCT03358875	NZ	2/12/2017	30/11/2017	taxane; anti-PD-1_monoclonal_antibody	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer	Tauranga; Hamilton; Wellington	https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03430063	NSW	9/02/2018	29/05/2018	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody			A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	- Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03454451	VIC, NSW, QLD	6/03/2018	25/04/2018	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	Non-Small Cell Lung Cancer; Renal Cell Cancer; Cervical Cancer; Endometrial Cancer; Pancreatic Cancer; Sarcoma; Colorectal Cancer; Ovarian Cancer; Metastatic Castration Resistant Prostate Cancer; Squamous Cell Carcinoma of the Head and Neck; Non-hodgkin Lymphoma; Bladder Cancer; Triple Negative Breast Cancer	2010 - Darlinghurst - St. Vincent's Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 3168 - Clayton - Monash Health; 3168 - Westmead - Westmead Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital	https://clinicaltrials.gov/ct2/show/NCT03454451
NCT03468426	VIC, NSW	16/03/2018	3/05/2018	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody; VEGF/Ang2-blocking_nanobody; anti-PD-1_monoclonal_antibody	BI836880 + Ezabenlimab	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody	An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors	Neoplasms; Non-squamous, Non-Small-Cell Lung Cancer	2065 - St Leonards - Royal North Shore Hospital; 2145 - Westmead - Westmead Hospital; 3004 - Melbourne - Alfred Hospital; 3199 - Frankston - Peninsula &amp; South Eastern Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03468426
NCT03497767	SA, QLD, NSW, VIC, WA	13/04/2018	15/08/2019	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	2002 - Sydney - Liverpool Hospital; 2010 - Sydney - St. Vincents Hospital - (Not yet recruiting); 2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Hospital; 2217 - Sydney - St George Hospital; 2298 - Newcastle - Calvary Mater; 3002 - Melbourne - Peter MacCallum Cancer Center; 3175 - Melbourne - Monash Health; 4102 - Brisbane - Princess Alexandra Hospital; 4120 - Brisbane - ICON Cancer Centre Greenslopes; Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Perth - Sir Charles Gairdner - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03497767
NCT03516981	WA, NSW, QLD	7/05/2018	1/10/2018	anti-CTLA-4_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Advanced Non-Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital Western Sydney Local Health District ( Site 0200) - (Completed); 4120 - Brisbane - Gallipoli Medical Research Foundation ( Site 0202) - (Completed); 6150 - Murdoch - Fiona Stanley Hospital ( Site 0201)	https://clinicaltrials.gov/ct2/show/NCT03516981
NCT03539536	WA, NSW, QLD	29/05/2018	10/10/2018	anti-c-Met_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-c-Met_antibody-drug_conjugate	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 207666; 2305 - Lambton Heights - Newcastle Private Hospital /ID# 206600; 2485 - Tweed Heads - The Tweed Hospital /ID# 206601; 4101 - South Brisbane - Mater Misericordiae Limited /ID# 229639; 6008 - Subiaco - St John Of God Subiaco Hospital /ID# 226943	https://clinicaltrials.gov/ct2/show/NCT03539536
NCT03549000	VIC	7/06/2018	18/07/2018	adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody	NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab	adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	Metastatic Castration Resistant Prostate Cancer (mCRPC); Triple Negative Breast Cancer (TNBC); Pancreatic Ductal Adenocarcinoma (PDAC); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer Microsatellite Stable (MSS); Ovarian Cancer; Renal Cell Carcinoma (RCC)	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03549000
NCT03611868	SA, QLD	2/08/2018	29/08/2018	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; p53-HDM2_interaction_inhibitor; MDM2_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	Alrizomadlin + Pembrolizumab	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Malignant Peripheral Nerve Sheath Tumors; Liposarcoma; P53 Mutation; Cutaneous Melanoma; MPNST; ATM Gene Mutation; Mucosal Melanoma; Uveal Melanoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Melanoma; STK11 Gene Mutation; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; MDM2 Gene Mutation	4101 - South Brisbane - Queensland Children's Hospital; 5042 - Bedford Park - Flinders Medical Centre; Brisbane - Metro South Hospital and Health Services via Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03611868
NCT03639714	VIC	21/08/2018	13/02/2019	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody			An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors	Urothelial Carcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Gastroesophageal Adenocarcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03639714
NCT03708328	NZ	17/10/2018	15/10/2018	bispecific_PD-1/TIM-3_antibody	RO7121661	bispecific_PD-1/TIM-3_antibody	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Small Cell Lung Cancer (SCLC); Solid Tumors; Non-small Cell Lung Cancer (NSCLC); Metastatic Melanoma	Auckland	https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03729596	QLD, NSW, VIC	2/11/2018	21/11/2018	anti-PD-1_monoclonal_antibody; anti-B7-H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7-H3_antibody-drug_conjugate	MGC018; MGC018 + Retifanlimab	anti-B7-H3_antibody-drug_conjugate; anti-B7-H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors	Melanoma; Non Small Cell Lung Cancer; Metastatic Castrate Resistant Prostate Cancer; Squamous Cell Carcinoma of Head and Neck; Advanced Solid Tumor, Adult; Triple Negative Breast Cancer	2010 - Darlinghurst - St Vincent's Health Network (Kinghorn Cancer Centre); 2298 - Waratah - Calvary Mater NewCastle; 3084 - Heidelberg - Austin Health - Olivia Newton John Cancer Center; 4105 - Woolloongabba - The University of Queensland - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT03729596
NCT03735121	NZ	8/11/2018	27/12/2018	anti-VEGF_monoclonal_antibody; recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT03735121
NCT03811652	VIC	21/01/2019	20/12/2018	anti-ASCT2_antibody-drug_conjugate; CYP17A1_inhibitor; antimetabolite; topoisomerase_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation; antimetabolite + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; antimetabolite + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Small Cell Lung Cancer (SCLC); Metastatic Castration-resistant Prostate Cancer (mCRPC)	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03893955	QLD	28/03/2019	21/05/2019	anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody + taxane; anti-CD40_agonist_antibody + platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel	anti-CD40_agonist_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + taxane	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors	Non-small-cell-lung-cancer (NSCLC); Advanced Solid Tumors; Triple-Negative Breast Cancer (TNBC); Cancer; Metastatic Solid Tumors	4101 - South Brisbane - Icon Cancer Centre /ID# 224084	https://clinicaltrials.gov/ct2/show/NCT03893955
NCT03906331	QLD, VIC, NSW, WA, NZ	8/04/2019		RET_inhibitor	Selpercatinib	RET_inhibitor	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Papillary Thyroid Cancer; Pancreatic Cancer; Medullary Thyroid Cancer; Breast Cancer; Non Small Cell Lung Cancer; Colon Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	2050 - Camperdown - NSW Health - Sydney Local Health District - (Available); 2065 - St. Leonards - Royal North Shore Hospital - (Available); 3000 - Melbourne - Peter MacCallum Cancer Centre - (Available); 4032 - Chermside - Queensland Health - Metro North Hospital and Health Service - (Available); 6009 - Nedlands - Linear Clinical Research Ltd - (Available); 91346 - Auckland - University of Auckland - (Available)	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03948763	NSW, VIC, NZ, SA	14/05/2019	26/06/2019	anti-PD-1_monoclonal_antibody + mRNA-derived_KRAS-targeting_vaccine; mRNA-derived_KRAS-targeting_vaccine; anti-PD-1_monoclonal_antibody	Pembrolizumab + mRNA-5671; mRNA-5671	anti-PD-1_monoclonal_antibody + mRNA-derived_KRAS-targeting_vaccine; mRNA-derived_KRAS-targeting_vaccine	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Colorectal Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 6500); 2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 6000); 3168 - Clayton - Monash Health-Monash Medical Centre ( Site 6001); 5042 - Bedford Park - Southern Oncology Clinical Research Unit SOCRU ( Site 6002); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 6501)	https://clinicaltrials.gov/ct2/show/NCT03948763
NCT03974022	WA, NSW, VIC	4/06/2019	9/07/2019	ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	DZD9008	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	NonSmall Cell Lung Cancer	Blacktown - Blacktown Hospital; Heidelberg - Austin Hospital; Kogarah - St George Hospital; North Melbourne - Peter MacCallum Cancer Centre - East Melbourne - (Not yet recruiting); Perth - Linear Cancer trials; Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT03976375	SA, VIC, NSW, QLD	6/06/2019	26/06/2019	taxane; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Metastatic Non-Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital ( Site 0005); 2148 - Blacktown - Blacktown Hospital ( Site 0004); 2444 - Port Macquarie - Port Macquarie Base Hospital ( Site 0003); 2500 - Wollongong - Southern Medical Day Care Centre ( Site 0001); 3552 - Bendigo - Bendigo Cancer Centre ( Site 0008); 4102 - Woolloongabba - Princess Alexandra Hospital - Division of Cancer Services ( Site 0002); 5112 - Elizabeth Vale - Calvary Central Districts Hospital ( Site 0007)	https://clinicaltrials.gov/ct2/show/NCT03976375
NCT03994393	SA, QLD, VIC, NSW, TAS	21/06/2019	23/10/2018	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody			A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	EGFR Mutant Advanced Non Small Cell Lung Cancer	Bankstown - Bankstown Hospital; Bedford Park - Flinders Medical Centre - (Not yet recruiting); Chermside - The Prince Charles Hospital; Clayton - Monash Medical Centre - Clayton; Gosford - Gosford Hospital; Hobart - Royal Hobart Hospital; Kogarah - St George Hospital; Liverpool - Liverpool Hospital; Melbourne - Peter MacCallum Cancer Centre; Melbourne - St Vincent's Hospital (Melbourne); Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03994393
NCT04000529	NSW	27/06/2019	30/07/2019	SHP2_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ribociclib + TNO155; Spartalizumab + TNO155	CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Esophageal SCC; Gastrointestinal Stromal Tumors; Colorectal Cancer; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Carcinoma	2145 - Westmead - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04000529
NCT04032704	TAS, VIC, NSW, QLD, Othe, SA	25/07/2019	9/10/2019	anti-LIV-1_antibody-drug_conjugate	Ladiratuzumab Vedotin	anti-LIV-1_antibody-drug_conjugate	Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Non-small Cell Lung Cancer, Squamous; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Cancer; Prostate Cancer; Melanoma; Non-small Cell Lung Cancer, Non-squamous	2010 - Sydney - St Vincents Hospital Sydney; 2250 - Gosford - Central Coast Local Health District (Gosford and Wyong Hospitals); 3144 - Malvern - Cabrini; 3199 - Frankston - Peninsula and South East Oncology; 4814 - Douglas - The Townsville Hospital; 5042 - Bedford Park - Flinders Medical Centre; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04032704
NCT04129502	NSW, TAS, QLD, SA	16/10/2019	6/01/2020	platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective; antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; ERBB2_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Mobocertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	2065 - St Leonards - Northern Cancer Institute, St Leonards; 2137 - Kogarah - St George Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04129502
NCT04151563	QLD, VIC, NSW, WA	5/11/2019		ROS1_inhibitor + anti-PD-1_monoclonal_antibody; taxane; ROS1_inhibitor; VEGFR2_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; KIT_inhibitor; VEGFR/PDGFR/FGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-1_monoclonal_antibody; RET_inhibitor; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR/FGFR1/2/3_inhibitor; anti-PD-1_monoclonal_antibody + taxane	Cabozantinib + Ipilimumab + Nivolumab; Cabozantinib + Nivolumab; Docetaxel; Docetaxel + Nivolumab; Docetaxel + Nivolumab + Ramucirumab; Lucitanib + Nivolumab	AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR/FGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; taxane	A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy	Carcinoma, Non-small Cell Lung Cancer	2010 - Darlinghurst; 2050 - Sydney; 2145 - Westmead; 6150 - Murdoch; 4029 - Herston; 3065 - Fitzroy; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT04151563
NCT04154956	QLD, NSW	7/11/2019	6/02/2020	anti-CEACAM5_antibody-drug_conjugate; taxane	Docetaxel; SAR408701	anti-CEACAM5_antibody-drug_conjugate; taxane	Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors	Non-small Cell Lung Cancer Metastatic	2148 - Blacktown - Investigational Site Number :0360002; 2298 - Waratah - Investigational Site Number :0360003; 4102 - Woolloongabba - Investigational Site Number :0360001	https://clinicaltrials.gov/ct2/show/NCT04154956
NCT04194944	QLD, VIC, NSW	11/12/2019	17/02/2020	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; RET_inhibitor; antimetabolite	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Selpercatinib	RET_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Melbourne - St. Vincent's Hospital; 3149 - Frankston - Slade Pharmacy - (Not yet recruiting); 3168 - Clayton - Monash Medical Centre; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04194944
NCT04222972	SA, NSW	10/01/2020	24/07/2020	antimetabolite; RET_inhibitor; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Pembrolizumab; Pralsetinib	RET_inhibitor; anti-PD-1_monoclonal_antibody	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer	Thoracic Neoplasms; Neoplasms, Nerve Tissue; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Lung Diseases; Lung Neoplasm; RET-fusion Non Small Cell Lung Cancer; Carcinoma; Head and Neck Neoplasms; Respiratory Tract Neoplasms; Neoplasms by Histologic Type; Neoplasms by Site; Bronchial Diseases; Carcinoma, Bronchogenic; Respiratory Tract Disease; Neoplasms; Adenocarcinoma	2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04222972
NCT04242199	NSW, VIC, WA	27/01/2020	20/08/2020				A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Cervical Cancer; MSI-H/dMMR Tumors; Merkel Cell Carcinoma; HepatoCellular Carcinoma; PD-L1 Amplified Tumor (9p24.1); Mesothelioma; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma; Small-cell Lung Cancer; Advanced Solid Tumor	02050 - Camperdown - Chris Obrien Lifehouse; 03004 - Melbourne - Nucleus Network Pty Ltd - (Completed); Heidelberg - Austin Hospital; Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04242199
NCT04248829	QLD	30/01/2020	13/02/2020	EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation; placebo	Gefitinib + Lazertinib	EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation	A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04248829
NCT04262856	NSW, SA	10/02/2020	28/05/2020	adenosine_A2aR_and_A2bR_antagonist; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	Squamous Non Small Cell Lung Cancer; Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Non Small Cell Lung Cancer	2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - Tweed Hospital; 2500 - Nowra - Shoalhaven Cancer Care Centre; 2640 - Albury - Border Medical Oncology; 5112 - Elizabeth Vale - Adelaide Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04262856
NCT04282018	NSW, VIC, WA, SA	24/02/2020	25/05/2020	BTK_inhibitor + PI3K_delta_inhibitor; anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor; BTK_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Diffuse Large B Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Metastatic Melanoma	2148 - Blacktown - Blacktown Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital; 5000 - Adelaide - a) Hematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital,; Clayton - Monash Hospital - Hematology; Darlinghurst - St. Vincent Hospital - Sydney - Hematology/Oncology; Heidelberg - Austin Hospital - Hematology; West Perth - Perth Blood Institute	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04294810	QLD, VIC, NSW	4/03/2020	4/03/2020	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; placebo	Atezolizumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney - (Active, not recruiting); 3000 - Melbourne - Peter Maccallum Cancer Centre; 3084 - Heidelberg - Austin Hospital Olivia Newton John Cancer Centre; 3199 - Frankston - Frankston Hospital; Oncology/Haematology - (Active, not recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04294810
NCT04300244	WA	9/03/2020	4/05/2020	anti-CTLA-4_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Cancer; Lung; Cancer, Lung; Pleura; Cancer of Lung; Mesotheliomas Pleural; Mesothelioma	Perth - University of Western Australia	https://clinicaltrials.gov/ct2/show/NCT04300244
NCT04383210	VIC	12/05/2020	29/09/2020	anti-ERBB3_monoclonal_antibody			CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Cholangiocarcinoma; Bile Duct Cancer; Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Bladder Cancer; Esophageal Cancer; Uterine Cancer; Kidney Cancer; Breast Cancer; Gallbladder Cancer; Head and Neck Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Sarcoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04383210
NCT04427072	VIC	11/06/2020	25/09/2020	taxane; MET_inhibitor,type_1	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14).	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne - Novartis Investigative Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04427072
NCT04430842	NSW	12/06/2020	20/07/2020	amino_acid_analogue,LAT1_targeting	QBS10072S	amino_acid_analogue,LAT1_targeting	A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma	Cholangiocarcinoma; Brain Cancer; Liver Cancer; Pleural Mesothelioma; Tongue Cancer; Cervical Cancer; Esophagus Cancer; Bladder Cancer; Thymic Carcinoma; Lung Cancer; Pancreatic Cancer; Gastric Cancer; Astrocytoma; Urinary Tract Cancer; Head and Neck Cancer; Breast Cancer; Brain Metastases; Kidney Cancer; Sarcoma; Melanoma; Colorectal Cancer; Ovarian Cancer; Prostate Cancer	2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04430842
NCT04432207	VIC, NSW	16/06/2020	30/11/2020	B_cell_immunotherapy	IMU-201	B_cell_immunotherapy	An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Adenocarcinoma Lung; Large Cell Carcinoma Lung; Non Small Cell Lung Cancer; Non-small Cell Lung Cancer Stage IV; Squamous Non-small-cell Lung Cancer; Non Small Cell Lung Cancer Stage IIIB	2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - Macquarie - Macquarie University; 3000 - Melbourne - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT04432207
NCT04434482	VIC, NSW	17/06/2020	7/08/2020	PARP_inhibitor + alkylating_agent; alkylating_agent; PARP_inhibitor	IMP4297 + Temozolomide	PARP_inhibitor + alkylating_agent	A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Small Cell Lung Cancer; Advanced Solid Tumours	2148 - Blacktown - Blacktown Hospital; 2640 - Albury - Border Medical Centre; 2800 - Orange - Orange Hospital; 3199 - Frankston - Peninsula Health - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04447118	Saint Leonard, SA, VIC, NSW, WA	25/06/2020	11/09/2020	ERBB2_inhibitor,second_generation; taxane; EGFR_inhibitor,exon_20_selective	Docetaxel; Pyrotinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,second_generation; taxane	A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	Non-squamous NSCLC; HER2 Exon 20 Mutation	Albury - Border Medical Oncology; Fitzroy - St Vincent's Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary North Adelaide Hospital; St Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04447118
NCT04449874	NZ, WA, VIC, NSW	29/06/2020	29/07/2020	KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,first_generation; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; SHP2_inhibitor	Atezolizumab + GDC-6036; Bevacizumab + GDC-6036; Cetuximab + GDC-6036; Erlotinib + GDC-6036; GDC-6036; GDC-6036 + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital - (Not yet recruiting); 2010 - Darlinghurst - St Vincent's Hospital Sydney - (Not yet recruiting); 3002 - East Melbourne - Peter MacCallum Cancer Center; 3004 - Melbourne - Alfred Health; 6009 - Nedlands - Linear Clinical Research Limited; 8011 - Christchurch - Christchurch Clinical Studies Trust Ltd - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04475939	TAS, VIC, NSW	17/07/2020	26/10/2020	PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	Niraparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)	Lung Cancer, Non-Small Cell	2148 - Blacktown - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 7000 - Hobart - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04475939
NCT04487080	WA, VIC, NSW, QLD, SA	27/07/2020	30/09/2020	EGFR_inhibitor,third_generation; bispecific_c-Met_EGFR_monoclonal_antibody; placebo; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	Amivantamab + Lazertinib; Lazertinib + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Carcinoma, Non-Small-Cell Lung	2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital - (Withdrawn); 2500 - Wollongong - Southern Medical Day Care Centre; 3084 - Heidelberg - Austin Hospital; 3144 - Malvern - Cabrini Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6150 - Murdoch - St John of God Hospital Murdoch; 6150 - Murdoch - St John of God Hospital Murdoch - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04487080
NCT04513925	SA, NZ, WA, VIC, NSW, QLD	14/08/2020	24/08/2020	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Durvalumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation	Non-small Cell Lung Cancer (NSCLC)	2148 - Blacktown - Blacktown Hospital; 2217 - Kogarah - St George Hospital; Cancer Care Centre; 2560 - Campbelltown - Macarthur Cancer Therapy Centre; 3143 - Tauranga - Tauranga Hospital; 3168 - Victoria - Monash Health Translational Precinct; Clinical Trials Centre, Level 3; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6149 - Bull Creek - Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04513925
NCT04524689	NSW, VIC	24/08/2020	26/10/2020	anti-CEACAM5_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed; Cisplatin + Pembrolizumab; Cisplatin + Pembrolizumab + Pemetrexed; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	2109 - Macquarie Park; 3081 - Heidelberg West	https://clinicaltrials.gov/ct2/show/NCT04524689
NCT04538664	WA, VIC, NSW	4/09/2020	13/10/2020	bispecific_c-Met_EGFR_monoclonal_antibody; antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite + bispecific_c-Met_EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent	Amivantamab + Carboplatin + Pemetrexed; Carboplatin + Pemetrexed	antimetabolite + bispecific_c-Met_EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown - Chris O'Brien Lifehouse; 2217 - Kogarah - St George Hospital; 3084 - Heidelberg - Austin Hospital - (Withdrawn); 3144 - Malvern - Cabrini Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04538664
NCT04585815	NSW, VIC	14/10/2020	10/11/2020	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; MEK_inhibitor; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive	Axitinib + Sasanlimab; Binimetinib + Encorafenib + Sasanlimab	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody	A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - North Shore Radiology and Nuclear Medicine; 2065 - St Leonards - Northern Cancer Institute; 2139 - Concord - Concord Hospital; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT04585815
NCT04612751	NSW, SA	3/11/2020	6/11/2020	anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	Datopotamab deruxtecan + Durvalumab	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Data-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Advanced or Metastatic NSCLC	2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04619004	QLD, VIC, NSW, WA	6/11/2020	2/02/2021	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor	2050 - Camperdown - The Chris O'Brien Lifehouse; 2148 - Blacktown - Blacktown Hosital; 2217 - Kogarah - St George Public Hospital - (Not yet recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04619004
NCT04623775	WA, NSW, VIC, NZ, QLD	10/11/2020	17/02/2021	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite	Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Non-small Cell Lunch Cancer; Metastatic Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer	2050 - Camperdown - The Chris OBrien Lifehouse; 2250 - Gosford - Gosford Hospital; 2340 - Tamworth - North West Cancer Centre in Tamworth; 3128 - Box Hill - Box Hill Hospital-Eastern Health; 3199 - Frankston - Frankston Hospital - peninsula Health; 3350 - Ballarat - Ballarat Health Services; 3550 - Bendigo - Local Institution; 4101 - South Brisbane - Icon Cancer Centre; 6009 - Nedlands - Hollywood Private Hospital; 6150 - Murdoch - St John of God Hospital - Murdoch; 8013 - Christchurch - Local Institution - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04623775
NCT04624204	NSW, VIC, QLD	10/11/2020	8/12/2020	glucocorticoid; placebo; radiotherapy; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor	Etoposide + Olaparib + Pembrolizumab + radiotherapy	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Na√Øve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	2298 - Waratah - Calvary Mater Newcastle ( Site 3000); 2560 - Campbelltown - Campbelltown Hospital ( Site 3002); 2750 - Penrith - Nepean Hospital ( Site 3001); 3021 - St Albans - Western Health-Sunshine Hospital ( Site 3004); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3006); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 3007); 4215 - Southport - Gold Coast University Hospital ( Site 3003)	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04644237	WA, QLD	25/11/2020	19/03/2021	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Non-Small Cell Lung Cancer	4102 - Woolloongabba - Princess Alexandra Hospital - (Not yet recruiting); 4814 - Townsville - Townsville University Hospital - (Not yet recruiting); 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT04644237
NCT04655976	VIC, NSW, TAS, QLD, SA	7/12/2020	8/12/2020	anti-PD-1_monoclonal_antibody + taxane; taxane; anti-PD-1_monoclonal_antibody	Docetaxel; Docetaxel + Dostarlimab	anti-PD-1_monoclonal_antibody + taxane; taxane	A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	Lung Cancer, Non-Small Cell	2148 - Blacktown - GSK Investigational Site; 3004 - Melbourne - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 4101 - South Brisbane - GSK Investigational Site; 5037 - Kurralta Park - GSK Investigational Site; 7000 - Hobart - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04655976
NCT04656652	NSW	7/12/2020	21/12/2020	taxane; anti-Trop2_antibody-drug_conjugate	DS-1062a; Docetaxel	anti-Trop2_antibody-drug_conjugate; taxane	Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)	Non-small Cell Lung Cancer	02109 - North Ryde - Macquarie Hospital; 02148 - Blacktown - Blacktown Hosital; 02500 - Wollongong - Southern Medical Day Care Centre; 03084 - Heidelberg - Austin Hospital; 04101 - South Brisbane - Icon Cancer Centre - (Withdrawn); 05042 - Bedford Park - Flinders Medical Centre; 2145 - Sydney - Crown Princess Mary Cancer Centre Westmead Hospital; 2217 - Kogarah - St George Public Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04656652
NCT04699188	VIC	7/01/2021	24/02/2021	KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor	JDQ443; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Neoplasms, Lung; Carcinoma, Non-Small-Cell Lung; Pulmonary Neoplasms; Lung Cancer; Neoplasms, Pulmonary; Carcinoma, Colorectal; Cancer of Lung; KRAS G12C Mutant Solid Tumors; Cancer of the Lung; Pulmonary Cancer	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04702880	NSW, VIC, WA, QLD	11/01/2021	17/03/2021	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; anti-fucosyl-GM1_monoclonal_antibody	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital-Department of Medical Oncology; 3004 - Melbourne - Local Institution - (Not yet recruiting); 4102 - Queensland - Gallipoli Medical Research Foundation-GMRF CTU; 6150 - Murdoch - St. John of God Murdoch Hospital-Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04713891	NSW	19/01/2021	9/03/2021	prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor	Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor	A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Gastric Cancer; Lung Cancer; Squamous Cell Carcinoma of the Esophagus; Bladder Cancer; Advanced Solid Tumor; Colorectal Cancer	2031 - Randwick - Scientia Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04721015	VIC, NSW	22/01/2021	18/02/2021	EGFR_inhibitor,third_generation; taxane	Docetaxel; Osimertinib	EGFR_inhibitor,third_generation; taxane	A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors	Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC)	2500 - Wollongong - Wollongong Hospital /ID# 228350 - (Not yet recruiting); 3084 - Heidelberg - Austin Health /ID# 225638	https://clinicaltrials.gov/ct2/show/NCT04721015
NCT04725188	ACT, WA, QLD	26/01/2021	20/04/2021	taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab + Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; taxane	A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy	Metastatic Non Small Cell Lung Cancer	2605 - Canberra - Canberra Hospital ( Site 0104); 4215 - Southport - Gold Coast University Hospital-Clinical Trials Service ( Site 0106); 6150 - Murdoch - Fiona Stanley Hospital-Medical Oncology ( Site 0102)	https://clinicaltrials.gov/ct2/show/NCT04725188
NCT04745689	NSW	9/02/2021	23/02/2021	topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Durvalumab	anti-PD-L1_monoclonal_antibody	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer	2250 - North Gosford - Research Site - (Not yet recruiting); 2500 - Wollongong - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04746924	QLD, WA, VIC, NSW, SA	10/02/2021	8/06/2021	anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Ociperlimab + Tislelizumab; Pembrolizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; NSCLC	2065 - Saint Leonards - Northern Cancer Institute, Genesis Care; 2139 - Concord - Concord Repatriation General Hospital; 2298 - Waratah - Calvary Mater Newcastle, Medical Oncology Trial Unit, Edith Street; 3021 - St Albans - Western Health - Sunshine Hospital; 3168 - Clayton - Monash Health - (Not yet recruiting); 3350 - Ballarat - Ballarat Health Services; 4032 - Chermside - The Prince Charles Hospital - (Not yet recruiting); 4101 - South Brisbane - Mater Cancer Care Centre - (Not yet recruiting); 4224 - Tugun - John Flynn Private Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6150 - Murdoch - St John of God, Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT04746924
NCT04801095	VIC, WA	16/03/2021	14/07/2021	mutant_receptor_tyrosine_kinase_inhibitor	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Colorectal Cancer; Head and Neck Cancer; Pancreatic Cancer; Lung Cancer; Metastatic Solid Tumor; Cholangiocarcinoma	3168 - Clayton - Monash Medical Center; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04801095
NCT04819100	QLD, NSW, VIC	26/03/2021	20/12/2021	RET_inhibitor; placebo	Selpercatinib	RET_inhibitor	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	Carcinoma, Non-Small-Cell Lung	2640 - Albury - Border Medical Oncology; 3280 - Warrambool - South West Healthcare; 3350 - Ballarat - Ballarat Health Services - Base Hospital; 3550 - Bendigo - Bendigo Health; 3630 - Shepparton - Goulburn Valley Health; 4575 - Birtinya - Sunshine Coast University Hospital - (Not yet recruiting); 4700 - Rockhampton - Rockhampton Hospital - (Not yet recruiting); 4814 - Douglas - The Townsville Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04819100
NCT04822298	NSW	30/03/2021	31/08/2021	PSMA_bispecific_T-cell_engager			A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer	NSCLC; Non-small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04822298
NCT04844073	SA, NSW, VIC	14/04/2021	8/03/2021	bispecific_T_cell_engager_targeting_EGFR	MVC-101	bispecific_T_cell_engager_targeting_EGFR	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA‚Ñ¢) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Colorectal Neoplasms	2031 - Randwick - Scientia Clinical Research Limited, Corner High &amp; Avoca Street, 5th Floor, Bright Building; 3052 - Melbourne - Peter MacCallum Cancer Centre, Grattan Street, Parkville, Medical Oncology, Level 2 - (Not yet recruiting); 3084 - Heidelberg - Austin Hospital, 145 Studley Road, Intensive Care Unit - (Not yet recruiting); 3168 - Clayton - Monash Health, Monash Medical Center, 246 Clayton Road - (Not yet recruiting); 5042 - Bedford Park - Southern Oncology Clinical Research Unit, 1 Flinders Drive	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04849273	WA, NSW, VIC	19/04/2021	2/08/2021	ALK_inhibitor,fourth_generation	TPX-0131	ALK_inhibitor,fourth_generation	A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC	Advanced Solid Tumor; NSCLC; Non Small Cell Lung Cancer; ALK Gene Mutation; Non-Small Cell Lung Cancer; Metastatic Solid Tumor	2148 - Blacktown - Blacktown Cancer and Hematology Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04849273
NCT04914897	VIC, NSW	7/06/2021	23/09/2021	platinum-based_antineoplastic_agent; taxane; IL-2_variant; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + taxane	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Nab-paclitaxel + Paclitaxel + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + taxane	A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma	Pleural Mesothelioma; Non-small Cell Lung Cancer	2109 - Macquarie Park - Investigational Site Number :0360001; 3121 - Richmond - Investigational Site Number :0360002	https://clinicaltrials.gov/ct2/show/NCT04914897
NCT04921358	SA, VIC, NSW, QLD	10/06/2021	27/07/2021	anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; taxane; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor	Docetaxel; Sitravatinib + Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane	A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody	Non-Small Cell Lung Cancer (NSCLC)	2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2217 - Kogarah - St George Hospital - (Not yet recruiting); 2560 - Campbelltown - Campbelltown Hospital - (Not yet recruiting); 3002 - East Melbourne - St Vincent's Hospital Melbourne - (Not yet recruiting); 3021 - Saint Albans - Sunshine Hospital, Western Health - (Not yet recruiting); 3076 - Epping - Northern Hospital - (Not yet recruiting); 4120 - Greenslopes - Gallipoli Medical Research Foundation (Greenslopes Private Hospital) - (Not yet recruiting); 4556 - Sippy Downs - University of the Sunshine Coast - (Not yet recruiting); 5000 - Adelaide - Cancer Research South Australia - (Not yet recruiting); Clayton - Monash Health - (Not yet recruiting); Tweed Heads - The Tweed Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04921358
NCT04995523	VIC	9/08/2021	14/09/2021	bispecific_PD-1/TIGIT_antibody	AZD2936	bispecific_PD-1/TIGIT_antibody	A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic Non-small Cell Lung Cancer	Non-Small-Cell Lung Carcinoma	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT05086692	NSW, VIC, QLD	21/10/2021	27/08/2021	IL-2_superkine	MDNA11	IL-2_superkine	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Uterine Cancer; Cholangiocarcinoma; Sarcoma; Biliary Tract Cancer; Unresectable Solid Tumor; Renal Cell Carcinoma; Non-Small Cell Lung Cancer Non-squamous; Basal Cell Carcinoma; Melanoma; Colorectal Cancer; Non-Small Cell Lung Cancer Squamous; Ovarian Cancer; Cutaneous Squamous Cell Carcinoma; Bladder Cancer; Advanced Solid Tumor; Cervical Cancer; Triple Negative Breast Cancer; Merkel Cell Carcinoma; Gastric Cancer; Gallbladder Cancer; Pancreatic Ductal Adenocarcinoma; Squamous Cell Carcinoma of Head and Neck	2031 - Randwick - Scientia Clinical Research; 2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 3144 - Malvern - Cabrini Research; 4101 - South Brisbane - ICON Cancer Center; 4120 - Greenslopes - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT04631731	NSW	10/11/2020					Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Lung Cancer, Nonsmall Cell; Renal Cell Carcinoma; Melanoma; Gastric Cancer; Hepatocellular Carcinoma; Endometrial Cancer; Mesothelioma	2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Mt Druitt Hospital	https://clinicaltrials.gov/ct2/show/NCT04631731
NCT04676828	NSW	15/12/2020					Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial	Lung Cancer; Radiation-Induced Disorder; Radiation Pneumonitis; Pulmonary Disease; Lung Function Decreased	2145 - Sydney - Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04676828
